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ABSTRACT 
Barrett’s esophagus is the precursor lesion of esophageal adenocarcinoma, a tumor with 
increasing incidence and poor prognosis. The overall aim of the thesis was to assess risk and 
prognosis in patients with Barrett’s esophagus and esophageal adenocarcinoma. Four studies 
were conducted based on data from Swedish nationwide registers and medical records from 
71 Swedish hospitals. 
Study I was a population-based cohort study which assessed the risk of esophageal 
adenocarcinoma among patients with Barrett’s esophagus. Among 7,932 study participants 
with Barrett’s esophagus (median age 66 years, 68% men), 89 developed esophageal 
adenocarcinoma. After excluding prevalent adenocarcinomas (70%), 27 adenocarcinomas 
developed over a period of 18,415 person-years, which corresponded to an incidence rate of 
1.5 (95% CI 0.9-2.0) cases per 1,000 person-years at risk and a standardized incidence ratio 
of 9.4 (95% CI 6.2-13.6). 
Study II was a population-based, nested case-control study designed to identify a prediction 
model for progression from Barrett’s esophagus to adenocarcinoma or high-grade dysplasia. 
All adenocarcinoma and high-grade dysplasia in patients with Barrett’s esophagus in Sweden 
were included as cases (n=279). Four randomly selected non-progressors per case were 
included as controls (n=1,089). For the included patients, endoscopy and histopathology 
records were collected and reviewed. Older age, male sex and longer Barrett’s esophagus 
segment length were associated with increased risk of adenocarcinoma/high-grade dysplasia. 
In contrast, hiatal hernia and esophagitis were not associated with tumor progression. A 
model based on age, sex and segment length predicted 71% of adenocarcinoma/high-grade 
dysplasia. 
Study III was a population-based cohort study which evaluated the adherence to surveillance 
and treatment guidelines for Barrett’s esophagus. All patients with dysplastic Barrett’s 
esophagus in Study II were included and followed for median 3.9 years using nationwide 
registers. Among 211 participants (71% low-grade dysplasia, 29% high-grade dysplasia), 
84% had a follow-up endoscopy, 17% received endoscopic therapy and 8% underwent 
esophagectomy. However, 60% were not managed in accordance with clinical guidelines, 
mainly due to under-surveillance. Risk factors for deviation from surveillance and treatment 
recommended in guidelines were low-grade dysplasia compared to high-grade dysplasia and 
longer segment length compared to shorter segment length, while treatment in surgical 
compared to gastroenterological departments was associated with recommended surveillance 
and treatment. 
Study IV was a population-based cohort study which assessed whether endoscopy screening 
improves the prognosis of esophageal adenocarcinoma. Among 6,600 study participants with 
adenocarcinoma (mean age 70 years, 79% male) followed for 9,138 person-years, 7% had a 
history of gastroesophageal reflux disease and 9% underwent endoscopy before cancer 
diagnosis. The 5-year mortality was decreased in patients with history of gastroesophageal 
reflux disease (HR 0.71, 95% CI 0.64-0.80), and this decrease was only slightly attenuated by 
adjustment for prior endoscopy (HR 0.79, 95% CI 0.70-0.90). The 5-year mortality was 
unchanged in patients with 1-2 screening endoscopies (compared to patients without 
screening endoscopy), while those with ≥3 endoscopies for gastroesophageal reflux disease 
had improved survival in esophageal adenocarcinoma (HR 0.55, 95% CI 0.36-0.85). 
To conclude, the overall risk of adenocarcinoma in Barrett’s esophagus is low, but it is 
possible to predict a clearly higher risk of tumor progression based on a few clinically 
available risk factors, enabling tailored endoscopy surveillance in these patients. Currently, 
adherence to recommended surveillance and treatment guidelines is poor, and efforts to 
implement these guidelines in clinical practice are needed. Use of endoscopy screening has a 
limited impact on survival in adenocarcinoma unless performed frequently. 
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 1 
 INTRODUCTION 
Barrett’s esophagus, a conversion from normal esophageal squamous epithelium to 
metaplastic columnar epithelium, develops due to chronic gastroesophageal reflux disease 
(GERD) and is prevalent in 1-2% of the population. Barrett’s esophagus is relevant as the 
precursor lesion of esophageal adenocarcinoma, a tumor with increasing incidence and poor 
prognosis. Because of the malignant potential, patients diagnosed with Barrett’s esophagus 
are enrolled in endoscopic surveillance to detect high-grade dysplasia or early 
adenocarcinoma. However, only a minute proportion of patients with Barrett’s esophagus 
will develop adenocarcinoma, and there is a great need to identify those at particularly high or 
low risk to better tailor the follow-up of these patients. 
This thesis contains four original studies of patients with Barrett’s esophagus and esophageal 
adenocarcinoma. These studies are based on nationwide medical registers linked to data from 
collected endoscopy and histopathology reports. The first study addresses the absolute risk of 
adenocarcinoma in Barrett’s esophagus. The second study provides a prediction model for 
tumor progression among patients with Barrett’s esophagus. The third study evaluates the 
adherence to surveillance and treatment guidelines for Barrett’s esophagus in clinical practice 
and the fourth study assesses whether use of endoscopy screening improves survival in 
esophageal adenocarcinoma. 
2 
 BACKGROUND 
2.1 STRUCTURE AND FUNCTION OF THE ESOPHAGUS 
The esophagus is an approximately 25 cm long and 2 cm wide muscular tube which connects 
the pharynx to the stomach. Its course is relatively straight, beginning posterior to the trachea 
and continuing down in front and slightly to the left of the vertebral column. The esophagus 
then passes through the posterior mediastinum behind the heart before exiting the thorax 
through the diaphragm.1 Its upper and lower ends are supplied with two sphincters which 
open during swallowing or vomiting. In addition, the lower esophageal sphincter functions as 
a reflux barrier, protecting the esophagus from acidic reflux from the stomach. From its 
lumen and out, the esophagus is divided into four tissue layers: mucosa, submucosa, 
muscularis propria and adventitia (but no serosal layer).2 The lumen is normally lined by 
stratified squamous epithelium, which is supported by the lamina propria and the connective 
tissue of the submucosa. Through an endoscope, the transition to stomach is demarcated by 
the gastric folds, which signals the border where the esophagus ends and the stomach begins. 
The transition from squamous to gastric columnar epithelium, and thus from esophagus to 
stomach, is visually apparent as a change in color from white to pink. 
 
2.2 THE AXIS OF PATHOLOGY: GASTROESOPHAGEAL REFLUX DISEASE, 
BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA 
2.2.1 Gastroesophageal reflux disease 
GERD is defined as “a condition that develops when the reflux of stomach contents causes 
troublesome symptoms and complications” according to a consensus definition (the Montreal 
definition).3 GERD is one of the most common health disorders with a prevalence of 15-25% 
of adults in Western countries.4, 5 The diagnosis can often be established based on a medical 
history with typical symptoms, i.e. heartburn or regurgitation, in combination with a positive 
response to anti-reflux medication with proton pump inhibitors.6 Severe GERD resistant to 
medication may be treated with surgery, i.e. fundoplication.7, 8  
Although GERD is generally considered a benign condition associated with mildly impaired 
quality of life, it may also cause potentially life-threatening complications.9, 10 Chronic GERD 
is a potent risk factor for esophageal adenocarcinoma, a tumor arising in the distal esophagus 
with very poor prognosis.11, 12 Esophageal adenocarcinoma is preceded by Barrett’s 
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esophagus, which is a metaplasia from the normal esophageal squamous epithelium to 
columnar epithelium. Barrett’s esophagus is typically visible upon standard white light 
endoscopy as a pink area stretching above the gastroesophageal junction.13 
 
2.2.2 Barrett’s esophagus 
2.2.2.1 History 
The condition is named after the Australian thoracic surgeon Norman Barrett, who described 
a columnar-lined esophagus in the case report “Chronic peptic ulcer of the oesophagus and 
'oesophagitis',” published in 1950.14 In the report, Barrett described the esophageal specimen 
of a young boy with an esophageal ulcer and surrounding columnar epithelium extending to 
the level of the aortic arch (Figure 1). This was likely not the first description of a columnar-
lined esophagus, as Barrett cited several previous case reports in his original study. Some 
contend that the first description was made in 1906 by the American pathologist Wilder 
Tileston, who described three cases of esophageal peptic ulcer and noted “the close 
resemblance of the mucous membrane about the ulcer to that normally found in the stomach,” 
also correctly attributing the cause of the lesion to gastroesophageal reflux.15, 16 Perhaps the 
most convincing early description of Barrett’s esophagus was provided by Alexander Lyall in 
Figure 1. Illustration of the esophageal specimen 
described by Norman Barrett in 1950. The presence of 
gastric folds surrounding the ulcer suggests that the 
columnar epithelium originated from an intrathoracic 
stomach rather than the esophagus. Reproduced with 
permission from Barrett.14 
Figure 2. Photograph of the esophageal specimen 
described by Alexander Lyall in 1937. The dark zone 
extending above the ulcer represents one of the first 
descriptions of Barrett’s esophagus. Reproduced with 
permission from Lyall.17. 
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1937, who described the esophageal specimen of Patrick C, a 58-year old male with long-
standing epigastric pain, weight loss, anemia and occasional vomiting of coffee ground 
material (Figure 2).17 Patrick C died from a bleeding esophageal ulcer, but Lyall noted that 
the mucosa surrounding the ulcer was “heterotopic gastric mucosa which extended as a 
tongue-shaped process of well-preserved tissue upwards from that of the fundus of the 
stomach,” a typical description of Barrett’s esophagus.17 Although Barrett did not claim to be 
the first to describe esophageal columnar epithelium or ulcers in such epithelium, Allison and 
Johnstone named the ulcers “Barrett’s ulcer” in a subsequent article in Thorax.18 By 
extension, the surrounding epithelium became known as Barrett’s esophagus.16, 19 
2.2.2.2 Definition and risk factors 
Barrett’s esophagus develops as a consequence of chronic gastroesophageal reflux to the 
lower esophagus, which induces an inflammatory response and a replacement of damaged 
esophageal squamous epithelium with acid-resistant columnar epithelium.13 A suspected 
diagnosis of Barrett’s esophagus is verified by biopsy, which may show three distinct forms 
of columnar epithelium: intestinal-type, cardia-type and gastric fundic-type. Most medical 
societies require intestinal-type epithelium, which contains prominent goblet cells, for the 
diagnosis of Barrett’s esophagus.20-23 This requirement is debated, and UK guidelines (among 
others) consider all metaplastic columnar epithelium above the gastroesophageal junction as 
Barrett’s esophagus.24 Compared to intestinal-type epithelium, cardia-type and gastric fundic-
type epithelium entail a lower risk of adenocarcinoma development.25 Until the late 1990s, 
Barrett’s esophagus was only considered for columnar epithelium extending an arbitrary 3 cm 
or more proximally, nowadays termed long-segment Barrett’s esophagus in contrast to short-
segment Barrett’s esophagus (shorter than 3 cm). Today, the metaplastic area is often 
described in a standardized manner according to the Prague C & M criteria, which outline the 
circumferential and maximum extent of the segment.26  
The metaplastic epithelium is further classified by the reviewing pathologist for presence and 
degree of dysplasia. The vast majority of Barrett’s esophagus is negative for dysplasia, which 
is associated with the lowest risk of esophageal adenocarcinoma.27, 28 Dysplastic lesions are 
categorized into low-grade or high-grade dysplasia, which are more immediate precursor 
lesions of adenocarcinoma and entail a higher risk of tumor progression. The annual risk of 
adenocarcinoma in low- and high-grade dysplasia is approximately 0.6% and 7%, 
respectively, although the reported risk of tumor progression differs substantially between 
studies.29, 30 The heterogeneity between studies is likely in part due to difficulties of 
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accurately determining degree of dysplasia.31, 32 A small proportion of biopsy specimens are 
classified as indefinite for dysplasia, which is a poorly studied condition. The risk of 
adenocarcinoma in these lesions seems to be somewhere between the risk in Barrett’s 
esophagus negative for dysplasia and low-grade dysplasia.33 
Barrett’s esophagus is prevalent in 1-2% of Western and Asian populations,34-36 but more 
frequently in those with GERD, in men, and in the elderly.37-39 Long segments are closely 
related to GERD symptoms, while short-segment disease often is asymptomatic.40 Short-
segment Barrett’s esophagus is more prevalent in the population, but often remains 
undiagnosed.34, 35 Obesity, in particular a central distribution of adipose tissue, increases the 
risk of Barrett’s esophagus by promoting GERD through mechanical effects on the lower 
esophageal sphincter, but may also increase the risk through the release of cytokines and 
growth factors from adipose tissue.41, 42 Weight loss decreases GERD, but whether the risk of 
Barrett’s esophagus decreases reciprocally is uncertain.43 Cigarette smoking increases the risk 
of Barrett’s esophagus in a dose-dependent manner, in part by relaxing the lower esophageal 
sphincter and increasing GERD.44 Infection with the bug Helicobacter pylori may lead to 
atrophy of the gastric corpus, thus decreasing production of gastric acid and the risk of 
Barrett’s esophagus.45, 46 Barrett’s esophagus also has a polygenic hereditary component and 
familial forms may be present in a minority of cases.47  
2.2.2.3 Surveillance and treatment 
Most patients with Barrett’s esophagus are followed with regularly spaced surveillance 
endoscopy with the purpose of detecting development of dysplasia or cancer at a curable 
stage and available for less extensive treatment. Based on the low absolute risk of 
progression, Barrett’s esophagus negative for dysplasia is followed every 3-5 years while 
those with dysplasia are followed more often or endoscopically treated outright.20-24 Patients 
enrolled in surveillance programs are diagnosed with adenocarcinoma at younger age and 
earlier tumor stage, which translates into improved survival.48-52 However, some of the 
improved survival associated with surveillance of Barrett’s esophagus may likely be 
attributed to lead and length time bias.52, 53 Large population-based studies in recent years 
have indicated that the risk of tumor progression to adenocarcinoma in Barrett’s is lower than 
previously reported, why the effectiveness and necessity of general surveillance have been 
questioned.54, 55  
Patients with Barrett’s esophagus are typically administered anti-reflux medication with 
proton pump inhibitors regardless of reflux symptoms. Proton pump inhibitors block the 
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H+/K+ ATPase enzyme of the gastric parietal cells, which normally transports hydrogen ions 
to the gastric lumen where it forms hydrochloric acid. The immediate effect is a decreased 
acidity of the gastric contents, which limits tissue injury to the esophageal epithelium. Proton 
pump inhibitors are generally considered safe56, 57 and most observational studies have 
indicated that use of these medications also decrease the risk of progression from Barrett’s 
esophagus to adenocarcinoma.58-61 However, a recent randomized trial failed to show a dose-
response effect of the proton pump inhibitor esomeprazole in preventing adenocarcinoma, 
which would be expected from a chemopreventive medication.62 
In addition, large-scale observational studies have indicated that use of aspirin and statins, 
which have anti-inflammatory properties, may prevent development of several forms of 
cancer, including esophageal adenocarcinoma.63-68 However, these preventive effects have 
not been reproduced convincingly in more recent studies.62, 69 
In the recent decade, the treatment arsenal available to physicians managing dysplastic 
Barrett’s esophagus has expanded. Patients with low-grade dysplasia previously underwent 
frequent surveillance endoscopy, but are now considered for endoscopic eradication therapy 
with radiofrequency ablation, which seems more effective than surveillance for the 
prevention of adenocarcinoma.70-72 High-grade dysplasia, previously treated with 
esophagectomy, is now treated with endoscopic methods, not the least radiofrequency 
ablation, which has superior efficacy to surveillance and is less invasive than open surgery.73, 
74 Mucosal irregularities in a dysplastic segment are generally treated with endoscopic 
mucosal resection or endoscopic submucosal dissection, which also aids staging of the tumor 
by determining invasion depth.75 
 
2.2.3 Esophageal adenocarcinoma 
Esophageal adenocarcinoma arises from Barrett’s esophagus (columnar cells in the distal 
esophagus) and is thus often located in close proximity to the gastroesophageal junction. 
Once a true clinical rarity, the incidence of adenocarcinoma has increased manifold since the 
1970s and had by the 1990s surpassed squamous cell carcinoma as the most common subtype 
of esophageal cancer in many Western countries.76-78 In 2012, 52,000 new cases of 
esophageal adenocarcinoma occurred worldwide, translating to an age-standardized incidence 
rate of 0.7 per 100,000 person-years at risk, but the tumor is considerably more common in 
developed countries (Figure 3).78, 79 Peak incidence occurs in Northern Europe, where almost 
50% of all cases are diagnosed.79  
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Figure 3. Global differences in age-standardized incidence rate (ASR) per 100,000 in men. Reproduced with permission from 
Arnold et al.79 
 
Risk factors for adenocarcinoma vastly overlap with those of Barrett’s esophagus, including 
old age, male sex, GERD, obesity, and tobacco smoking, while infection with Helicobacter 
pylori seems to be protective for adenocarcinoma development.12, 42, 80, 81 GERD, which is the 
strongest risk factor, increases the risk by five to eight times, but is not reported by 40% of 
patients with adenocarcinoma.11, 12 The tumor has a pronounced male predominance, 
although the sex ratio varies considerably across geographical regions.79 The excess risk for 
men in the US is 9:1, which is stronger than in any other non-sex-specific cancer.82 The cause 
of the male predominance remains largely unclear, but the increased severity of GERD and 
the higher prevalence of abdominal obesity and tobacco use among men might contribute. 
Sex hormonal factors may also explain some of the strong male predominance.83 
Upper endoscopy with biopsy is the gold standard for confirming the diagnosis of 
adenocarcinoma. Although GERD is the most frequent indication for referral to endoscopy, 
the increased use of endoscopy screening has had a modest or non-existent effect on tumor 
stage in patients diagnosed with adenocarcinoma (Figure 4).84, 85 Early symptoms of 
adenocarcinoma are scarce and >75% of patients present with advanced disease, when 
symptoms such as dysphagia, weight loss and fatigue become apparent.85 Nevertheless, the 
overall 5-year survival in esophageal adenocarcinoma has increased from 5% in the 1960s to 
20% today in Europe and the US, in part due to improvements in curatively intended 
treatment.86, 87 
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Figure 4. Stage distribution of incident cases of esophageal adenocarcinoma between 1975 and 2009 based on SEER data 
from the US. Reproduced with permission from Hur et al.85 
 
Tumor stage is assessed by endoscopy, endoscopic ultrasound, computed tomography and 
positron emission tomography. Endoscopic resection may provide a sample collection for T-
staging and histopathological assessment in early tumors.88 Superficial lesions confined to the 
mucosa (T1a) permits endoscopic resection followed by eradication of the remaining 
Barrett’s esophagus segment, which decreases the risk of recurrence.89 Tumors invading deep 
into the submucosa or further into the muscularis propria are treated with esophagectomy.76, 77 
In locally advanced tumors (T3), surgery is generally preceded by neoadjuvant chemo- or 
chemoradiotherapy, which improves survival compared to surgery alone.90, 91 Esophagectomy 
is usually performed by a combined laparotomy or laparoscopy and thoracotomy or 
thoracoscopy and sometimes also a neck incision, where most of the esophagus is resected 
and replaced by a gastric conduit (or a colon interposition) anastomosed to the remaining 
proximal esophagus.77 For tumors invading the tissue surrounding the esophagus (T4), distant 
metastatic disease or in patients not fit to undergo surgery, palliative treatment with chemo- 
or chemoradiotherapy is the treatment of choice, while stenting may be used to relieve 
dysphagia.76, 77 
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 AIMS 
The overall aim of the thesis was to assess risk and prognosis among patients with Barrett’s 
esophagus and esophageal adenocarcinoma. 
The specific aims of the included studies were: 
• To assess the absolute risk of esophageal adenocarcinoma in patients with Barrett’s 
esophagus. 
• To develop a model which predicts esophageal adenocarcinoma and high-grade 
dysplasia in patients with Barrett’s esophagus. 
• To evaluate adherence to surveillance and treatment guidelines for Barrett’s 
esophagus in clinical practice. 
• To assess whether use of endoscopy screening of GERD facilitates early detection of 
esophageal adenocarcinoma and thus improves survival in this cancer. 
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 METHODS 
4.1 OVERVIEW 
 
Table 1. Methods overview of the included studies. 
 Study I Study II Study III Study IV 
Short title Risk of 
adenocarcinoma 
in Barrett’s  
Prediction model 
for 
adenocarcinoma 
in Barrett’s  
Adherence to 
guidelines in 
Barrett’s 
Endoscopy use 
and survival in 
adenocarcinoma 
Design Population-
based cohort 
study 
Population-
based nested 
case-control 
study 
Population-
based cohort 
study 
Population-
based cohort 
study 
Data sources Patient Register, 
Cancer Register, 
Register of the 
Total Population 
Patient Register, 
Cancer Register, 
Prescribed Drug 
Register, 
medical records 
Patient Register, 
Cancer Register, 
Cause of Death 
Register, 
Prescribed Drug 
Register, 
medical records 
Patient Register, 
Cancer Register, 
Cause of Death 
Register 
Study 
participants 
Barrett’s 
esophagus 
Barrett’s 
esophagus 
Barrett’s 
esophagus 
Esophageal 
adenocarcinoma 
Exposure Barrett’s 
esophagus 
Age, sex, 
segment length, 
hiatal hernia, 
esophagitis 
Age, sex, 
comorbidity, 
degree of 
dysplasia, 
segment length, 
calendar period, 
department, 
hospital 
GERD, 
endoscopy  
Main outcome Esophageal 
adenocarcinoma 
Esophageal 
adenocarcinoma/
high-grade 
dysplasia 
Deviation from 
surveillance 
guidelines 
Disease-specific 
5-year mortality 
Secondary 
outcome(s) 
Esophageal 
adenocarcinoma/
high-grade 
dysplasia 
Esophageal 
adenocarcinoma,  
high-grade 
dysplasia 
Under-
surveillance, 
over-
surveillance 
All-cause 5-year 
mortality, 
surgical 
resection 
Inclusion 
period 
2006-2013 2006-2013 2006-2013 1997-2013 
End of follow-
up 
2014 2014 2014 2016 
Main statistical 
analysis 
Standardized 
incidence ratio 
Multivariable 
logistic 
regression, 
prediction 
modelling 
Multivariable 
logistic 
regression 
Multivariable 
Cox regression, 
logistic 
regression 
Abbreviations: GERD – gastroesophageal reflux disease 
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4.2 DATA SOURCES 
The studies in this thesis were based on data from two main sources: nationwide Swedish 
registers and medical records collected from hospitals managing patients with Barrett’s 
esophagus. The registers and medical records were linked by the personal identity number, 
which was used for patient identification in both data sources as well as for data linkages. A 
personal identity number is assigned to all people permanently residing in Sweden and is 
unique to each individual. 
 
4.2.1 The Patient Register 
The Patient Register was established in 1964-1965 and was nationwide from 1987. The 
register is held by the National Board of Health and Welfare and contains demographic data, 
such as patient age and sex, diagnoses according to the International Classification of 
Diseases (ICD), procedures and information on the treating healthcare from all specialized 
out-hospital healthcare (from 2001) and in-hospital healthcare. Diagnoses and procedures are 
coded and registered by the discharging physician and electronically transferred to the 
National Board of Health and Welfare. Data from the Patient Register have been validated for 
their usefulness in population-based studies and diagnostic codes linked to procedures are 
generally well covered.92 
 
4.2.2 The Cancer Register 
The Cancer Register was established in 1958 and contains data on all incident cancers in 
Sweden. The register holds tumor-specific data, such as site, histopathology, stage (since 
2005) and date of diagnosis. The register has been validated for the registration of esophageal 
and gastric cardia adenocarcinoma with 98% completeness for registration, 100% 
completeness for histopathology reporting and 98% completeness for tumor stage.93-95 
 
4.2.3 The Cause of Death Register 
This register has recorded date and cause of all deaths in Swedish residents since 1952. The 
register is 100% complete for date of death and 99% complete for cause of death.96, 97 Cause 
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of death is registered on a yearly basis with a time lag, while date of death is continuously 
updated.  
 
4.2.4 The Prescribed Drug Register 
This register was started in July 2005 and holds data about all prescribed drugs in Sweden. 
The register is electronically recorded by Swedish pharmacies and quality controlled by the 
Swedish eHealth Agency. Given the automaticity and quality control, the accuracy and 
completeness of the register data are almost 100%.98 
 
4.2.5 The Register of the Total Population 
This register holds information about date of birth, date of death, date of emigration and 
current residency status, and is continuously updated. This register was used for censoring 
purposes. 
 
4.2.6 Medical records 
Endoscopy and histopathology reports of 1,368 patients with Barrett’s esophagus were 
obtained from 71 Swedish hospitals and manually reviewed. Data on date and indication for 
endoscopy, length of the Barrett’s esophagus segment, hiatal hernia and esophagitis were 
extracted from the endoscopy reports. The histopathology reports were assessed for 
metaplasia, dysplasia and inflammation. 
 
4.3 STUDY DESIGN 
4.3.1 Study I 
4.3.1.1 Design 
This was a population-based cohort study of all patients with a recorded diagnosis of 
Barrett’s esophagus in the Swedish Patient Register during the study period. Data were 
 13 
retrieved from the Patient Register, the Cancer Register and the Register of the Total 
Population. 
4.3.1.2 Study cohort 
The study cohort was identified by the ICD code for Barrett’s esophagus in the Patient 
Register between January 1, 2006 and December 31, 2013. Among 8,189 identified patients 
with Barrett’s esophagus, those with missing information on date of diagnosis (n=4), younger 
than 30 years at diagnosis (n=99) or with a history of high-grade dysplasia or esophageal 
adenocarcinoma (n=154) were excluded from the study cohort, resulting in 7,932 patients 
available for analysis. 
4.3.1.3 Outcome 
The main outcome was esophageal adenocarcinoma, while the secondary outcome was the 
compound endpoint of adenocarcinoma or high-grade dysplasia. The outcomes were defined 
from the Cancer Register by the ICD codes for esophageal or gastric cardia cancer in 
combination with histology codes for adenocarcinoma or high-grade dysplasia. 
4.3.1.4 Statistical analysis 
Follow-up started on the date of Barrett’s esophagus diagnosis and ended at adenocarcinoma 
or high-grade dysplasia diagnosis, death or end of study period, whichever occurred first. 
Incidence rates were calculated as cases per 1,000 person-years at risk with 95% confidence 
intervals (CI). For the main analysis, participants with adenocarcinoma or high-grade 
dysplasia within one year of Barrett’s esophagus diagnosis were excluded, because these 
were considered to have prevalent cancer or dysplasia. Standardized incidence ratios (SIR) 
with 95% CI of adenocarcinoma were calculated to compare the risk in the Barrett’s 
esophagus cohort with the expected risk assessed from the background population. The SIRs 
were calculated by dividing the observed number of adenocarcinomas in the Barrett’s 
esophagus cohort by the expected number. The expected number was derived from the 
Cancer Register and defined as the number of adenocarcinoma cases that would occur in the 
Barrett’s esophagus cohort if the incidence rate for adenocarcinoma was the same as of the 
background population of the same age, sex and calendar year. The expected number was 
obtained by multiplying the observed person-time by age (in 5-year groups), sex and calendar 
year-specific incidence rates in the general population. 
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4.3.2 Study II 
4.3.2.1 Design 
This was a population-based, nested case-control study in a cohort of patients with Barrett’s 
esophagus. Data were retrieved from the Patient Register, the Cancer Register, the Prescribed 
Drug Register and from medical records. 
4.3.2.2 Study cohort 
Figure 5 shows a flowchart for the identification and selection of study participants. The 
study cohort was derived from the nationwide cohort of 8,189 patients diagnosed with 
Barrett’s esophagus described in Study I. Cases were patients with esophageal 
adenocarcinoma or high-grade dysplasia as identified from the Cancer Register. Four controls 
per case were randomly identified from the remaining cohort without tumor progression 
during follow-up. The index date of Barrett’s esophagus was identified, and endoscopy and 
histopathology reports from this date were retrieved from all hospitals managing these 
patients.  
 
 
Figure 5. Flowchart of the selection of study participants available for final analysis in Study II. 
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4.3.2.3 Predictors of tumor progression 
Five variables were considered to be potentially relevant for a prediction model: age, sex, 
length of the Barrett’s esophagus segment, hiatal hernia and esophagitis. These variables 
were retrieved from the endoscopy report. In addition, the Patient Register was searched for 
previous diagnoses of hiatal hernia or reflux esophagitis. 
4.3.2.4 Outcomes 
The main outcome was the compound endpoint of adenocarcinoma or high-grade dysplasia, 
while secondary outcomes were adenocarcinoma or high-grade dysplasia separately. 
Adenocarcinoma and high-grade dysplasia were identified by the corresponding ICD and 
histology codes in the Cancer Register. 
4.3.2.5 Statistical analysis 
Logistic regression was used to determine crude and adjusted odds ratios (OR) with 95% CI 
for the association between all outcomes and the five potential predictors of tumor 
progression. For categorical variables, the assumed lowest risk category was used as 
reference. The accuracy of the model was assessed by fitting a receiver operating 
characteristic (ROC) curve. In addition to a complete case analysis, the main analysis used 
multiple imputation to address missing data on segment length (10%). 
 
4.3.3 Study III 
4.3.3.1 Design 
This was a population-based cohort study of patients with dysplastic Barrett’s esophagus. 
Data were retrieved from the Patient Register, the Cancer Register, the Cause of Death 
Register, the Prescribed Drug Register and from medical records. 
4.3.3.2 Study cohort 
Figure 6 shows a flowchart for the identification and selection of study participants. The 
study cohort consisted of all patients with dysplastic Barrett’s esophagus identified in Study 
II. Excluded were patients with a history of esophageal adenocarcinoma, indefinite for 
dysplasia, dysplasia without evidence of specialized intestinal metaplasia and those ineligible 
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for surveillance because of a too short follow-up due to death, early diagnosis of 
adenocarcinoma or end of study period. 
 
 
Figure 6. Flowchart of the selection of study participants available for final analysis in Study III. Abbreviations: EAC – 
esophageal adenocarcinoma. 
 
4.3.3.3 Risk factors 
Eight variables were considered as risk factors for deviation from guidelines: age, sex, 
comorbidity, degree of dysplasia, Barrett’s esophagus segment length, calendar period, 
hospital type and department type. Comorbidities were accumulated and categorized 
according to the Charlson Comorbidity Index.99 
4.3.3.4 Outcomes 
The main outcome was deviation from the surveillance and treatment recommended in 
clinical guidelines for dysplastic Barrett’s esophagus.20, 22, 100-102 For patients with low-grade 
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dysplasia, adherence to guidelines was defined as repeat endoscopy with biopsy within 6-12 
months of baseline assessment. Adherence to guidelines in patients with high-grade dysplasia 
was defined as repeated endoscopy with biopsy, endoscopic eradication therapy or 
esophagectomy within 3 months of baseline assessment. Management other than this was 
classified as deviation from guidelines. The secondary outcomes were under- and over-
surveillance assessed separately. Under-surveillance was defined by either lack of endoscopic 
surveillance or treatment first after the recommended time interval. Over-surveillance was 
defined as repeat endoscopy before the recommended time interval. Data on endoscopy, 
endoscopic eradication therapy and esophagectomy were accessed from the Patient Register.  
4.3.3.5 Statistical analysis 
Follow-up started on the date of index endoscopy with biopsy and ended at date of death, 
diagnosis of esophageal adenocarcinoma or end of study period, whichever occurred first. 
Logistic regression was used to determine crude and adjusted ORs with 95% CI for the 
association between risk factors and outcomes. For categorical variables, the assumed lowest 
risk category was used as reference. The main model provided ORs adjusted for age, sex, 
segment length, comorbidity, calendar period, hospital and department.  
 
4.3.4 Study IV 
4.3.4.1 Design 
This was a population-based cohort study of patients with esophageal adenocarcinoma in 
Sweden. Data were retrieved from the Patient Register, the Cancer Register and the Cause of 
Death Register.  
4.3.4.2 Study cohort 
The study cohort included all patients with a diagnosis of esophageal adenocarcinoma 
identified from the Cancer Register between January 1, 1997 and December 31, 2013. 
Participants with a diagnosis of Barrett’s esophagus, who are enrolled in endoscopic 
surveillance, were excluded. 
4.3.4.3 Exposures 
GERD was identified in the Patient Register by a set of ICD codes, including heartburn, 
gastroesophageal reflux disease, esophagitis, esophageal ulcer and esophageal obstruction. 
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Endoscopy was identified in the Patient Register, where endoscopies within 10 years prior to 
adenocarcinoma were counted. GERD and endoscopy within 3 months of adenocarcinoma 
were censored in order to exclude early adenocarcinoma misclassified as GERD and to 
exclude any endoscopy part of the work-up of an already existing adenocarcinoma. 
4.3.4.4 Confounders and mediators 
Age, sex, calendar-year and comorbidity were adjusted for, where comorbidity was 
categorized using the Charlson Comorbidity Index.99 Prior endoscopy, tumor stage and 
surgical resection were assessed as potential mediators between GERD and 5-year mortality. 
4.3.4.5 Outcomes 
The main outcome was disease-specific 5-year mortality, defined as the time from 
adenocarcinoma diagnosis until death specifically related to the tumor. Secondary outcomes 
were all-cause 5-year mortality and surgical resection of the tumor. All-cause 5-year 
mortality was defined as the time from adenocarcinoma diagnosis until death from any cause. 
Data on date and cause of death were retrieved from the Cause of Death Register. Surgical 
resection was defined by procedure codes corresponding to endoscopic or surgical resection 
of the esophagus or stomach in the Patient Register. 
4.3.4.6 Statistical analysis 
Follow-up started on the date of adenocarcinoma diagnosis and ended at date of death, end of 
study period or 5 years after cohort entry, whichever occurred first. The product limit 
estimates of the disease-specific 5-year survivor function were calculated for the exposures 
separately. Cox regression was used to determine crude and adjusted hazard ratios (HR) with 
95% CI for the association between exposures and mortality outcomes. The odds of 
undergoing surgical resection were assessed using logistic regression, which provided crude 
and adjusted ORs with 95% CI. The main models provided HRs and ORs adjusted for age, 
sex, calendar year and comorbidity. To evaluate effect modification of GERD of the 
associations between endoscopy and the outcomes, an interaction term was included for 
GERD and endoscopy. The HR and OR were then calculated separately for patients with and 
without GERD. 
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 RESULTS 
5.1 STUDY I 
Among 7,932 study participants with a diagnosis of Barrett’s esophagus followed for 18,415 
person-years, median age was 66 years and 68% were male (Table 2). During the follow-up, 
89 study participants developed esophageal adenocarcinoma and 61 developed high-grade 
dysplasia. Most adenocarcinoma (n=62) and high-grade dysplasia (n=34) were diagnosed 
within one year of Barrett’s esophagus diagnosis and were considered prevalent. 
 
 
After excluding tumors diagnosed within one year of the diagnosis of Barrett’s esophagus, 
the incidence rate of adenocarcinoma was 1.5 (95% CI 0.9-2.0) per 1,000 person-years at 
risk, with a median time to diagnosis of 2.5 years (Table 3). The standardized incidence ratio 
of esophageal adenocarcinoma was 9.4 (95% CI 6.2-13.6). The incidence rate of the 
compound endpoint adenocarcinoma or high-grade dysplasia was 3.0 (95% CI 2.2-3.7) per 
1,000 person-years at risk, with a median time to diagnosis of 2.0 years. High-grade dysplasia 
always occurred with a diagnosis of Barrett’s esophagus, and standardized incidence ratio for 
this outcome was thus not possible to calculate.  
 
Table 2. Characteristics of 7,932 study participants with Barrett’s esophagus. 
 Number (%) 
Age (years)  
30-49 866 (10.9) 
50-69 4,209 (53.1) 
≥70 2,857 (36.0) 
Sex  
Women 2,572 (32.4) 
Men 5,360 (67.6) 
Adenocarcinoma  
≤1 year of Barrett’s esophagus diagnosis 62 (69.7) 
>1 year of Barrett’s esophagus diagnosis 27 (30.3) 
Median age at diagnosis (years) 70.0 
High-grade dysplasia  
≤1 year of Barrett’s esophagus diagnosis 34 (55.7) 
>1 year of Barrett’s esophagus diagnosis  27 (44.3) 
Median age at diagnosis (years) 68.0 
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Table 3. Risk of esophageal adenocarcinoma and high-grade dysplasia among 7,932 
participants with Barrett’s esophagus. 
 Events Person-years at 
risk 
Incidence ratea 
(95%CI) 
Standardized incidence ratio 
(95%CI) 
Adenocarcinoma 
Total 27 18,415 1.47 (0.91-2.02) 9.36 (6.16-13.61) 
Age (years)    
30-49 4 1,782 2.24 (0.04-4.44) 188.86 (50.81-483.52) 
50-69 9 9,599 0.94 (0.33-1.55) 7.46 (3.40-14.17) 
≥70 14 7,034 1.99 (0.95-3.03) 8.44 (4.61-14.16) 
Sex     
Women 5 6,041 0.83 (0.10-1.55) 17.02 (5.49-39.72) 
Men 22 12,374 1.78 (1.03-2.52) 8.49 (5.32-12.85) 
High-grade dysplasia 
Total 27 18,424 1.47 (0.91-2.02) N/A 
Age (years)    
30-49 4 1,778 2.25 (0.04-4.45) N/A 
50-69 12 9,617 1.25 (0.54-1.95) N/A 
≥70 11 7,029 1.56 (0.64-2.49) N/A 
Sex     
Women 7 6,028 1.16 (0.30-2.02) N/A 
Men 20 12,396 1.61 (0.91-2.32) N/A 
aPer 1,000 person-years 
 
5.2 STUDY II 
After retrieval of medical records from 71 Swedish hospitals, the final study cohort consisted 
of 279 cases of adenocarcinoma/high-grade dysplasia and 1,089 controls with Barrett’s 
esophagus. The participation proportion was 90%. Mean age was 65 years and 71% were 
male (Table 4). The diagnosis of Barrett’s esophagus was verified by endoscopy with biopsy 
in 81% of index endoscopies, of which 96% showed metaplastic columnar cells. 
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Table 5 shows adjusted ORs with 95% CIs for the primary and secondary outcomes. In the 
multivariable analysis, older age, male sex and increasing segment length at diagnosis were 
associated with increased risk of adenocarcinoma and/or high-grade dysplasia. A prediction 
model based on the variables age, sex and segment length predicted 71% of the compound 
endpoint adenocarcinoma or high-grade dysplasia (Figure 7), 75% of all adenocarcinoma and 
68% of all high-grade dysplasia. Hiatal hernia and reflux esophagitis did not improve the 
model (Table 5). 
 
 Figure 7. Prediction model of progression to adenocarcinoma or high-grade dysplasia (EAC/HGD) among patients with 
Barrett's esophagus (BE) described in a receiver operating characteristic curve. AUC –area under the curve 
Table 4. Characteristics of 1,368 study participants with Barrett’s esophagus. 
 Number (%) 
 EAC 
(n=151) 
HGD  
(n=128) 
Controls 
(n=1,089) 
Age (years) – mean (standard deviation) 67.5 (10.5) 68.1 (10.8) 64.3 (12.1) 
Sex    
Women 17 (11.3) 20 (15.6) 358 (32.9) 
Men 134 (88.7) 108 (84.4) 731 (67.1) 
Segment length (cm) – median (interquartile range)    
Maximum 6 (4-10) 5 (2-10) 2 (1-5) 
Circumferential 4 (0-8) 2 (0-7) 0 (0-2) 
Hernia size (cm) – median (interquartile range) 4 (2-5) 3 (3-5) 3 (2-5) 
Esophagitis  71 (47.0) 85 (66.4) 598 (54.9) 
Abbreviations: EAC – esophageal adenocarcinoma, HGD – high-grade dysplasia 
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Table 5. Prediction of esophageal adenocarcinoma or high-grade dysplasia (EAC/HGD) 
after multiple imputation (including participants with missing data). 
 Number (%)  
 EAC/HGD 
(n=279) 
Controls 
(n=1,089) 
Adjusteda odds ratio with 
95%CI 
Age (year)    
Continuous - - 1.02 (1.01-1.03) 
Sex    
Women 37 (13.3) 358 (32.9) 1.0 (Reference) 
Men 242 (86.7) 731 (67.1) 2.8 (1.9-4.1) 
Segment length    
Ultra-short (<1 cm) 23 (8.2) 195 (17.9) 1.0 (Reference) 
Short (1 to <3 cm) 45 (16.1) 338 (31.0) 1.1 (0.7-1.9) 
Long (3 to <8 cm) 97 (34.8) 302 (27.7) 2.3 (1.4-3.9) 
Ultra-long (≥8 cm) 89 (31.9) 143 (13.1) 4.3 (2.5-7.2) 
Hiatal hernia    
No 60 (21.5) 219 (20.1) 1.0 (Reference) 
Yes 219 (78.5) 870 (79.9) 0.8 (0.6-1.1) 
Esophagitis    
No 123 (44.1) 491 (45.1) 1.0 (Reference) 
Yes 156 (55.9) 598 (54.9) 1.1 (0.8-1.4) 
aAdjusted for age, sex, maximum segment length, hiatal hernia, esophagitis 
 
5.3 STUDY III 
Among 211 study participants with Barrett’s esophagus followed for median 3.9 person-years 
(interquartile range 2.2-5.6 years), 149 (71%) had low-grade dysplasia and 62 (29%) had 
high-grade dysplasia. Mean age was 67 years and 81% were male (Table 6). Surveillance of 
Barrett’s esophagus was the most common indication for endoscopy (62%) and 46% had 
undergone two or more previous endoscopies. 
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In total, 84% of the participants underwent a follow-up endoscopy, 17% underwent 
endoscopic therapy and 8% underwent esophagectomy during follow-up (Table 7). However, 
60% of all participants were not followed-up or treated in adherence to guidelines, mainly 
due to underutilization of surveillance (86%). Median time to first follow-up endoscopy was 
9 months, to endoscopic treatment 13 months and to esophagectomy 17 months. 
 
 
 
Table 6. Characteristics of 211 study participants with dysplastic Barrett’s esophagus. 
 Number (%) 
 LGD 
(n=149) 
HGD 
(n=62) 
Age (years) – mean (standard deviation) 66.3 (9.2) 68.7 (10.8) 
Sex   
Women 32 (21) 8 (13) 
Men 117 (79) 54 (87) 
Charlson comorbidity index   
0 87 (58) 31 (50) 
≥1 62 (42) 31 (50) 
Segment length (cm) – median (interquartile range)   
Maximum 5 (2-9) 5 (3-9) 
Circumferential 1 (0-6) 3.5 (0-9) 
Hiatal hernia 110 (74) 52 (84) 
Abbreviations: HGD – high-grade dysplasia, LGD – low-grade dysplasia 
Table 7. Clinical management of 211 participants with dysplastic Barrett’s esophagus. 
 Number (%) 
 LGD 
(n=149) 
HGD  
(n=62) 
Deviation from surveillance guidelines 103 (69) 24 (39) 
Under-surveillance 85 (83) 24 (100) 
Over-surveillance 18 (17) 0 (0) 
Follow-up endoscopy 117 (79) 60 (97) 
Endoscopic therapy 12 (8) 24 (39) 
Esophagectomy 5 (3) 12 (19) 
Death 12 (8) 15 (24) 
Median time to follow-up endoscopy (in months) 13 3 
Median time to endoscopic therapy (in months) 39 7 
Median time to esophagectomy (in months) 26 6 
Abbreviations: HGD – high-grade dysplasia, LGD – low-grade dysplasia 
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Table 8 shows risk factors for deviation from clinical guidelines. Low-grade dysplasia and 
long-segment Barrett’s esophagus were associated with increased odds of deviation from 
guidelines compared to high-grade dysplasia and short-segment Barrett’s esophagus, 
respectively. In addition, deviation from guidelines was more common in gastroenterological 
departments in comparison to surgical departments. 
 
Table 8. Risk factors for deviation from guidelines in 211 participants with dysplastic 
Barrett’s esophagus. 
 Number (%)  
 Deviation from 
guidelines 
(n=127) 
Adherence to 
guidelines 
(n=84) 
Adjusteda odds 
ratio with 95%CI 
Age (years)    
<65 47 (37) 34 (40) 1 (Reference) 
≥65 80 (63) 50 (60) 1.1 (0.6-2.1) 
Sex    
Men 100 (79) 71 (85) 1 (Reference) 
Women 27 (21) 13 (15) 1.4 (0.6-3.1) 
Comorbidity    
0 70 (55) 48 (57) 1 (Reference) 
≥1 57 (45) 36 (43) 1.7 (0.8-3.5) 
Dysplasia    
High-grade 24 (19) 38 (45) 1 (Reference) 
Low-grade 103 (81) 46 (55) 3.4 (1.7-6.8) 
Segment length    
Short (<3 cm) 34 (30) 30 (40) 1 (Reference) 
Long (≥3 cm) 80 (70) 45 (60) 2.0 (1.0-3.9) 
Department    
Surgery 51 (40) 53 (63) 1 (Reference) 
Gastroenterology 70 (55) 29 (34) 2.3 (1.2-4.4) 
Other 6 (5) 2 (3) 8.1 (0.7-91.5) 
aAdjusted for age, sex, comorbidity, the degree of dysplasia, segment length, calendar period, 
hospital and department. 
 
5.4 STUDY IV 
Among 6,600 study participants with newly diagnosed esophageal adenocarcinoma followed 
for 9,138 person-years (mean 1.4 years), median age was 70 years and 79% were male (Table 
9). Of all participants, 7% had a history of GERD and 9% had undergone at least one 
endoscopy before adenocarcinoma diagnosis. 
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Table 9. Characteristics of 6,600 study participants with esophageal adenocarcinoma. 
 Number (%) 
 GERD 
(n=440) 
No GERD 
(n=6,160) 
Age (years)    
≤55 38 (8.6) 765 (12.4) 
56-65 112 (25.5) 1,448 (23.5) 
66-75 136 (30.9) 1,879 (30.5) 
≥76 154 (35.0) 2,068 (33.6) 
Sex   
Women 83 (18.9) 1,281 (20.8) 
Men 357 (81.1) 4,879 (79.2) 
Charlson comorbidity index   
0 260 (59.1) 4,209 (68.3) 
1 111 (25.2) 1,368 (22.2) 
≥2 69 (15.7) 583 (9.5) 
Tumor stagea   
I 52 (22.5) 225 (6.4) 
II 66 (21.0) 597 (17.1) 
III-IV 126 (40.0) 1,932 (55.3) 
Unstaged 71 (22.5) 739 (21.2) 
Surgical resection of adenocarcinoma 166 (37.7) 2,030 (33.0) 
aTumor stage data were available for patients diagnosed with adenocarcinoma in 2005-2013 
(n=3,808) 
Abbreviations: GERD – gastroesophageal reflux disease 
 
The cumulative proportion of death in adenocarcinoma was decreased for participants with 
GERD and in participants with ≥3 previous endoscopies (Figure 8 and 9). Moreover, the 
adjusted 5-year mortality in adenocarcinoma was decreased in participants with GERD 
compared to those without GERD (adjusted HR 0.71, 95% CI 0.64-0.80). This association 
was only slightly attenuated by further adjustment for previous endoscopies (adjusted HR 
0.79, 95% CI 0.70-0.90), tumor stage and surgical resection (adjusted HR 0.74, 95% CI 0.62-
0.89). Patients with GERD had increased odds of surgical resection (adjusted OR 1.39, 95% 
CI 1.13-1.71), which remained after adjustment by previous endoscopies (adjusted OR 1.30, 
95% CI 1.01-1.67). 
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Figure 8. Cumulative disease-specific mortality after diagnosis of esophageal adenocarcinoma among patients with and 
without gastroesophageal reflux disease (GERD). 
 
 
 
Figure 9. Cumulative disease-specific mortality after diagnosis of esophageal adenocarcinoma stratified by number of 
endoscopies prior to esophageal adenocarcinoma. 
 
The adjusted HR for mortality in adenocarcinoma among participants with GERD was 
virtually unaltered for 1 or 2 previous endoscopies compared to 0 endoscopies, while ≥3 
previous endoscopies was associated with decreased 5-year mortality (Table 10). The odds 
ratio of surgical resection increased with number of previous endoscopies in patients in 
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GERD, but was not statistically significant (Table 10). In participants without GERD, 
endoscopies were not associated with 5-year mortality or surgical resection (Table 11). 
 
Table 10. Risk of disease-specific 5-year mortality and surgical resection rates among 
440 participants with esophageal adenocarcinoma and gastroesophageal reflux disease 
 Number (%) 
 No endoscopy 1 endoscopy 2 endoscopies ≥3 endoscopies 
 170 (38.6) 168 (38.2) 56 (12.7) 46 (10.5) 
5-year mortalitya 
(HR, 95%CI) 
1 (Reference) 1.0 (0.8-1.3) 0.9 (0.6-1.3) 0.6 (0.4-0.9) 
Surgical resectiona 
(OR, 95%CI) 
1 (Reference) 0.7 (0.4-1.1) 1.2 (0.6-2.3) 1.9 (0.9-3.7) 
aAdjusted for age, sex, calendar year and comorbidity 
Abbreviations: HR – hazard ratio, OR – odds ratio 
 
Table 11. Risk of disease-specific 5-year mortality and surgical resection rates among 
6,160 participants with esophageal adenocarcinoma and no gastroesophageal reflux 
disease 
 Number (%) 
 No endoscopy 1 endoscopy 2 endoscopies ≥3 endoscopies 
 5,838 (94.8) 285 (4.6) 31 (0.5) 6 (0.1) 
5-year mortalitya 
(HR, 95%CI) 
1 (Reference) 0.9 (0.8-1.0) 0.9 (0.6-1.4) 1.0 (0.4-2.3) 
Surgical resectiona 
(OR, 95%CI) 
1 (Reference) 0.9 (0.7-1.2) 1.7 (0.8-3.6) 0.6 (0.1-5.5) 
aAdjusted for age, sex, calendar year and comorbidity 
Abbreviations: HR – hazard ratio, OR – odds ratio 
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 METHODOLOGICAL CONSIDERATIONS 
6.1 STUDY DESIGN 
Clinical research is conducted either by experimental or observational design. Experimental 
studies are most often conducted as randomized controlled trials, while cohort and case-
control designs are common in observational studies and were used for this thesis. If the 
sample size is large enough, randomized studies typically leads to two (or more) groups of 
participants which are alike in all aspects but one – the exposure status – which allows for a 
direct causal interpretation of the relation between exposure and outcome. In contrast, the 
exposed and non-exposed participants in observational studies are often different, which 
introduces a risk of confounding (discussed below). While the investigator in observational 
studies attempts to control for confounding, the obtained measure of association may not 
always be causally interpreted because of the influence of residual confounding factors. 
Nevertheless, observational studies hold many advantages compared to randomized studies 
and may be conducted in settings where randomized studies are not feasible. Some exposures 
are not possible to randomize, e.g. due to ethical or biological reasons, and rare outcomes 
may be unsuited to study because of the vast study sample size required to randomize to 
obtain precise results. Randomized studies are often limited to strict inclusion criteria, why 
the results may not always be inferred to an intended source population or generalizable to 
other populations. In contrast, observational studies may allow for the study of unselected and 
large study populations, which increases the external validity and precision and also allows 
for a number of exposures and outcomes to be examined in the same cohort. 
 
6.2 INTERNAL VALIDITY 
Internal validity refers to how well the observed estimate or association from the sampled 
study population represents the true estimate or association in the source population. The 
internal validity of a study may be compromised by a set of errors typically categorized into 
two main subheadings: systematic error, further subcategorized into selection bias, 
information bias and confounding, and random error.  
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6.2.1 Selection bias  
Selection bias is a systematic error which occurs when the participants in a study are a 
selected subpopulation which does not represent the population that the results are inferred 
upon. The consequence might be that the association between exposure and outcome among 
the included participants is different from the association in those eligible for the study.103  
Typically, the risk of selection increases when participation is voluntary or patients are lost to 
follow-up. In this thesis, follow-up was complete in all studies due to the use of nationwide 
registers. Study I and IV were nationwide studies and included virtually all patients in 
Sweden diagnosed with Barrett’s esophagus and adenocarcinoma, which minimized 
selection. Study II and III consisted of all patients with adenocarcinoma or high-grade 
dysplasia within the Barrett’s esophagus cohort, and a random sample of patients without 
dysplasia or low-grade dysplasia. Medical records were unavailable for a tenth of the 
included participants, which introduces a small risk of selection. Data were also missing for 
some the variables obtained from medical records, including segment length, hiatal hernia 
size and severity of esophagitis. Multiple imputation analysis was used to account for the 
limited missing data on segment length, but the proportion of missing was substantial for 
hiatal hernia size and severity of esophagitis. To minimize selection and preserve internal 
validity, hiatal hernia size and grade of esophagitis were not studied as predictors of tumor 
progression. 
 
6.2.2 Information bias 
Information bias refers to the misclassification of study variables. Information bias can be 
non-differential, meaning that the misclassification is equal among the comparison groups in 
a study. Non-differential misclassification results in an underestimation, or dilution, of the 
effect size. Differential misclassification, where the assessment of exposure or outcome 
varies over groups, is more unpredictable and may bias the measure of association in any 
direction. In contrast to selection bias, the amount of misclassification can be estimated in 
comparison to a gold standard, often described by the sensitivity or specificity.104 Sensitivity 
describes the probability of detecting an outcome in an individual with the outcome, while 
specificity describes the probability of testing negative in an individual without the outcome. 
The registers used in this thesis have been extensively validated with good results, including 
specific validation of the diagnosis of adenocarcinoma, which should reduce the risk of 
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misclassification. Further, the diagnosis of Barrett’s esophagus was validated by manual 
review of medical records in Study II and III. 
 
6.2.3 Confounding 
Confounding occurs when the exposure is associated with a variable which also impacts on 
the outcome, but is not along the causal pathway from exposure to outcome. Confounding is 
a problem in most observational studies because of the risk of residual confounding by 
unknown variables which cannot be adjusted for. However, known confounders can be 
managed in a few different ways. Confounding may be handled prior to sampling by 
matching on the confounding variable. After data collection, confounding can be managed by 
stratification on the confounding variable or by adjusting for confounding variables in 
multivariable regression models. For the first three studies in this thesis confounding was a 
minor problem. Study I and III were descriptive studies and Study II was a prediction model. 
In a prediction model, confounding by other variables is less relevant as long as the model 
performs well. However, other predictors for esophageal adenocarcinoma, such as smoking 
and obesity, could have improved the model but are only registered in medical registers in the 
odd case. In Study IV, GERD was associated with improved survival in adenocarcinoma after 
adjustment for most established prognostic factors. However, the mechanism for the 
improved survival is largely unknown and may well be the result of residual confounding by 
unknown factors associated with both GERD and survival in adenocarcinoma rather than 
GERD itself. 
 
6.2.4 Random error 
After eliminating any systematic error, random error may influence the internal validity of a 
study. The amount of random error in a study is described by the precision, which in turn is 
described by the confidence interval. The 95% confidence interval indicates that if a study 
was repeated and free from systematic error, it would contain the true measure within the 
interval 95% of the time. If the interval is narrow, there is high precision and thus low amount 
of random error, and vice versa. Large sample sizes, typically available in nationwide studies, 
narrow the confidence interval and reduce the amount of random error.  
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The p-value, which is complementary to the 95% confidence interval, describes the 
probability of rejecting a true null hypothesis in the absence of systematic non-random error 
(type I error). A p-value below 0.05 is traditionally considered satisfactory and leads to a 
rejection of the null hypothesis in favor of the alternative hypothesis. Importantly, hypothesis 
testing never provides a definitive rejection of the null hypothesis, but rather only a 
probability that the null hypothesis is true or false.104  
Although Study III was based on all high-grade dysplasia and a significant proportion of low-
grade dysplasia in Sweden, the rarity of known dysplastic Barrett’s esophagus resulted in a 
small sample size, which limited the precision of the study. Thus, the confidence intervals 
were wide, with an entailing increased risk of rejecting a true alternative hypothesis (type II 
error).  
 
6.3 EXTERNAL VALIDITY 
In contrast to internal validity, which concerns inference from the study population to the 
source population, external validity concerns inference from the study population to other 
populations or settings (generalizability). All studies in this thesis were population-based in 
design and had high participation rates, which means that results are highly generalizable to 
the Swedish population and to settings similar to Sweden. 
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 GENERAL DISCUSSION 
7.1 STUDY I 
The main finding of Study I was that the absolute risk of tumor progression in Barrett’s 
esophagus is low compared to historical estimates, which adds to similar research published 
in recent years.27, 28 Historically, the risk of adenocarcinoma in Barrett’s esophagus had been 
estimated to be up to 3% per person-year at risk.105 The cause of the much lower incidence of 
adenocarcinoma reported in recent years is likely attributable to several causes. First, a 
systematic review and meta-analysis suggested that the risk of adenocarcinoma reported in 
historical studies was overestimated due to suspected publication bias.105 Second, the 
expansion of the definition of Barrett’s esophagus to also include short segments should 
decrease the risk estimates, because short-segment Barrett’s esophagus is associated with a 
lower risk of adenocarcinoma compared to long-segment Barrett’s esophagus.106-109 Third, 
the increasing use of high-dose proton pump inhibitors may decrease tumor progression in 
Barrett’s esophagus.60, 61 In contrast, the use of preventive endoscopic therapy likely had a 
limited impact, given that radiofrequency ablation for low-grade dysplasia was not 
recommended until more recently.  
A surprising finding of the study was the unexpectedly high proportion of patients diagnosed 
with adenocarcinoma within one year of Barrett’s diagnosis, which was comparable to the 
proportion in a similarly designed Danish population-based study.28 The high proportion of 
early diagnosed adenocarcinoma is likely a result of prevalent adenocarcinomas missed upon 
initial diagnosis of Barrett’s esophagus. A recent meta-analysis estimated the proportion of 
missed adenocarcinomas diagnosed within one year of Barrett’s esophagus to 25%, but with 
considerably heterogeneous results in-between studies.110 There is no apparent systematic 
explanation for the heterogeneity, which is stable over calendar-year, study setting and 
geographical origin.110 Nevertheless, this finding highlights the importance of awareness of 
early neoplasia in Barrett’s esophagus. Early neoplasia is notoriously difficult to detect, but 
training by fairly simple means may improve detection rates considerably.111 The availability 
of advanced diagnostic tools to promptly detect neoplasia in Barrett’s esophagus, such as 
narrow-band imaging and wide area trans-epithelial sampling may also improve the detection 
rate.112, 113  
Only a minute proportion of all esophageal adenocarcinomas in Sweden during the study 
period arose in patients diagnosed with Barrett’s esophagus. The proportion of 
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adenocarcinomas with a known previous diagnosis of Barrett’s esophagus was lower 
compared to previous reports,114 which is worrying because adenocarcinoma presenting 
without a prior diagnosis of Barrett’s esophagus is associated with a dismal prognosis.  
Among the study’s methodological strengths were the nationwide design, the large sample 
size and the complete follow-up. Paired with the use of validated registers, the study secured 
results which should be generalizable to similar Western populations. Among the limitations 
were the inability to stratify the cohort for low-grade dysplasia and the relatively short 
median follow-up time. Yet, the impact of including Barrett’s esophagus with low-grade 
dysplasia should be limited because 90-95% of Barrett’s esophagus is negative for dysplasia 
and the risk of adenocarcinoma in low-grade dysplasia is only moderately increased.29 
 
7.2 STUDY II 
Study II showed that it may be possible to tailor surveillance of Barrett’s esophagus by using 
readily available demographic and endoscopic variables. Tailoring of surveillance programs 
in Barrett’s esophagus is highly needed, given that the vast majority of patients will not 
progress to adenocarcinoma, rendering general surveillance inefficient and costly.54, 55  The 
main finding was that 71% of esophageal adenocarcinoma and high-grade dysplasia could be 
explained by three variables: age, sex and maximum segment length, which was comparable 
to and adds support to simultaneously published clinical prediction models.115, 116 While the 
precision was fair, the model needs improvement for use in clinical practice. A recent meta-
analysis of risk factors for tumor progression in Barrett’s esophagus indicated that apart from 
older age, male sex, and longer segment length, cigarette smoking and low-grade dysplasia 
increase the risk of tumor progression to esophageal adenocarcinoma, while use of proton-
pump inhibitors or statins decrease the risk.109 However, incorporation of these additional risk 
factors in more complex models had a limited effect on the model performance. The addition 
of smoking and low-grade dysplasia to age, sex and segment length only resulted in a 
modestly improved prediction model in a multicenter study from the US and the 
Netherlands.115 In another study from the US, which added use of proton pump inhibitors and 
history of esophageal candidiasis to the model, the performance of the prediction model was 
also similar.116 Taken together, the results from this thesis and recently published clinical 
models imply that additional factors, such as biomarkers, are needed to improve the 
performance of future prediction models.117, 118 
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Apart from outlining the prediction model, the study demonstrated with good precision that 
once Barrett’s esophagus is diagnosed, neither hiatal hernia nor esophagitis are risk factors 
for progression to esophageal adenocarcinoma. Thus, while hiatal hernia and esophagitis are 
part of the causal pathway from GERD to esophageal adenocarcinoma, the presence or 
history of these lesions are less important once Barrett’s esophagus has developed, which is a 
clinically valuable finding. 
A third contribution of this study was the validation of the ICD code for Barrett’s esophagus 
in the Patient Register. Overall, the proportion of patients biopsied and the presence of 
metaplastic epithelium in vast the majority of biopsy specimens indicated overall good 
quality of the diagnosis code in the Patient Register. Nevertheless, only one endoscopy per 
study participant was reviewed, and any subsequent or precedent endoscopy could further 
improve the validity of the ICD code in the Patient Register. 
This was one of the largest studies to date assessing endoscopic risk factors for tumor 
progression in Barrett’s esophagus. Among the methodological strengths were the extensive 
data collection and the large sample size, which allowed for precise risk estimates. The 
nationwide design, high participation rate and low proportion of missing data resulted in a 
study cohort with low risk of selection bias. Possibly, additional clinical variables which were 
not available could have improved the performance of the model. Information on proton 
pump inhibitor medication was available, but was not evaluated because of the ubiquitous use 
among the study participants. Moreover, a substantial proportion of patients did not have 
specialized intestinal metaplasia upon index endoscopy. This could limit the generalizability 
to the broader definition of Barrett’s esophagus recommended by the British Society of 
Gastroenterology, which defines Barrett’s esophagus as all metaplastic columnar epithelium 
above the gastroesophageal junction.24 
 
7.3 STUDY III 
The main finding of Study III was that while gastroenterological societies recommend 
surveillance or outright treatment of Barrett’s esophagus with dysplasia, these guidelines are 
often not enforced in clinical practice. Several risk factors for deviation from guidelines were 
identified. Compared to Barrett’s esophagus with low-grade dysplasia, adherence was better 
in high-grade dysplasia, indicating that the physicians are stricter in the management of high-
risk lesions. Long-segment Barrett’s esophagus was associated with underutilization of 
surveillance and treatment, but has conversely been associated with overutilization of 
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surveillance endoscopy in non-dysplastic Barrett’s esophagus.119 Somewhat surprisingly, 
clinical guidelines were less strictly enforced in gastroenterological departments compared to 
surgical departments. While surgeons may be more commonly involved in high-grade 
dysplasia or early adenocarcinoma, this association was robust and remained after adjustment 
for baseline dysplasia. Speculatively, because gastroenterologists often are medically 
responsible for the surveillance of Barrett’s esophagus, they might more often consciously 
deviate from guidelines. Questionnaire data have indicated that gastroenterologists mostly 
adhere to guidelines, but tailor the surveillance further based on the endoscopic 
appearance.120, 121 
This study expands on previous studies of adherence to surveillance guidelines in non-
dysplastic Barrett’s esophagus, which is reported to be poor.119, 122-124 Surveillance of 
Barrett’s esophagus is associated with improved outcomes in adenocarcinoma, why efforts to 
improve adherence to guidelines in clinical practice are beneficial and needed.52 
Methodological strengths of the study included the population-based design, the extensive 
data collection, validation of the diagnosis of Barrett’s esophagus through manual review of 
histopathology reports and the complete follow-up. Limitations include that in some cases 
deviation from guidelines may have been voluntary due to patient frailty and refusal by the 
patient to participate. While this would result in a deviation from guidelines, it should not be 
considered inappropriate management. Despite the nationwide design, the sample size was 
relatively small, which resulted in wide confidence intervals and risk of type II errors. 
Whether these variables are associated with poor surveillance and treatment should be 
assessed in larger studies or meta-analyses. 
 
7.4 STUDY IV 
The main findings of Study IV were that GERD was associated with improved prognosis in 
esophageal adenocarcinoma, but that the increased use of endoscopy screening in these 
patients did not explain the improved survival. Survival was virtually unaltered in patients 
with 1-2 endoscopies before adenocarcinoma diagnosis, while survival improved 
substantially in patients with GERD and ≥3 endoscopies before adenocarcinoma diagnosis. 
Previous literature has provided sparse and contradictory data on whether endoscopy 
screening for GERD improves survival in esophageal adenocarcinoma. The aggressive nature 
of esophageal adenocarcinoma leaves a short time window for detection, requiring perfect 
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timing of the endoscopy to detect curable cancer. In addition, the tumor often develops 
without symptoms, why the detection of early stage adenocarcinoma represents a major 
challenge to most physicians. Nevertheless, a high rate of referral for endoscopy in a general 
practice setting has been associated with improved outcomes in esophageal and gastric 
cancer.125 In smaller studies, a screening endoscopy for GERD within a few years of 
esophageal adenocarcinoma diagnosis has been associated with earlier tumor stage and 
increased surgical resection rates.126, 127 In this study, the use of endoscopy was not associated 
with improved survival unless performed frequently, which indicates a limited role for 
endoscopy screening in the prevention of mortality in esophageal adenocarcinoma. A group 
of patients at high risk of adenocarcinoma may benefit from repeat endoscopy for GERD, 
although it remains a challenge to select these patients and the ideal interval for endoscopies. 
Repeated endoscopy for other indications than GERD should have a similar effect on 
detecting adenocarcinoma, although the study was not powered to verify or reject this 
hypothesis. Nevertheless, a history of GERD was associated with improved survival in 
adenocarcinoma, although the improved prognosis was not explained by increased use of 
endoscopy screening or earlier tumor stage in these patients. While established prognostic 
factors were adjusted for, the improved survival in GERD-associated adenocarcinoma may 
be due to residual confounding by other factors such as health-conscious behavior or therapy 
associated with GERD. 
Methodological strengths of the study included the nationwide design, which secured an 
unselected, large cohort with complete follow-up, and the possibility to assess the impact of 
multiple endoscopies for GERD. Among the limitations was the inability to account for some 
potential confounding factors which might explain the improved prognosis in GERD-related 
adenocarcinoma. Further, the occurrence of GERD was likely underestimated, because 
GERD is not always reported by patients. It is likely that less severe GERD remained 
undiagnosed and more severe GERD was registered. Because those with less severe GERD 
were considered unexposed, this should dilute the association between GERD and mortality 
in adenocarcinoma. 
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 CONCLUSIONS 
• The absolute risk of esophageal adenocarcinoma in Barrett’s esophagus is limited, 
particularly after the first year of diagnosis, indicating that general surveillance of 
these patients may be ineffective. 
• By using clinical patient characteristics such as age, sex and length of the Barrett 
segment, it is possible to identify patients at increased risk of adenocarcinoma and 
tailor surveillance programs. 
• Surveillance and treatment guidelines for the management of Barrett’s esophagus are 
poorly followed in clinical practice, which indicates that efforts to implement 
guidelines should be made. 
• GERD is associated with improved outcomes in esophageal adenocarcinoma, but the 
use of endoscopy screening in these patients does not improve survival in 
adenocarcinoma unless performed repeatedly. These findings indicate that other 
strategies to detect curable adenocarcinoma are needed. 
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 FUTURE DIRECTIONS 
Prediction modelling based on clinical factors have indicated that further risk stratification of 
Barrett’s esophagus is possible with some accuracy.115, 116, 128 However, these models need to 
be improved to more confidently exclude patients with low risk of adenocarcinoma from 
surveillance programs. Research in recent years has identified an abundance of biomarkers in 
esophageal tissue and blood associated with tumor progression in Barrett’s esophagus.117, 118, 
129, 130 A combination of clinical variables and biomarkers could improve current models and 
should be further evaluated in future studies.  
Two further strategies may be used to decrease mortality in esophageal adenocarcinoma. 
First, efforts to implement guideline recommendations for surveillance and treatment of 
Barrett’s esophagus in clinical practice should be made, because appropriate surveillance of 
Barrett’s esophagus likely leads to improved survival in adenocarcinoma.52 Second, the 
detection of Barrett’s esophagus needs to be improved. While endoscopic screening based on 
GERD may be invasive, costly and ineffective, preliminary data from non-endoscopic 
screening methods for the detection of Barrett’s esophagus have shown promising results.131-
135 The use of such minimally invasive methods may move the diagnostic tools for 
identifying Barrett’s esophagus from endoscopists in specialized healthcare to a primary care 
setting, thus increasing the availability significantly.  
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  POPULÄRVETENSKAPLIG SAMMANFATTNING 
10.1 BAKGRUND 
Sjuklig grad av halsbränna, även kallat gastroesofageal refluxsjukdom, är mycket vanligt och 
kan oftast behandlas framgångsrikt med receptfria mediciner. Refluxsjukdom är för det mesta 
ett godartat tillstånd, men i ett fåtal fall kan långvariga besvär ge upphov till en cancertyp i 
matstrupen (körtelcancer). Förekomsten av denna typ av matstrupscancer har de senaste 
decennierna ökat snabbt, vilket troligen delvis beror på den ökade förekomsten av övervikt, 
vilket kan orsaka besvär med reflux. Matstrupscancer är en symptomfattig tumörsjukdom 
med mycket aggressivt förlopp, vilket innebär att många diagnosticeras sent i förloppet. 
Således är prognosen dålig och endast ca 20 % lever fem år efter diagnos. Tumören föregås 
av utbredda förändringar i matstrupens slemhinna som kallas Barretts esofagus, synligt för 
ögat som en rödare slemhinna vid gastroskopi. Detta tillstånd finns hos 1-2% av alla vuxna. 
Patienter med Barretts esofagus följs med upprepade gastroskopier för att diagnosticera, 
förebygga och behandla matstrupscancer i botbart skede. Den stora majoriteten av patienter 
med Barretts utvecklar dock aldrig matstrupscancer och följs därför i onödan.  
Det övergripande målet med den här avhandlingen var att utvärdera risk och prognos för 
matstrupscancer hos patienter med Barretts esofagus. För detta ändamål användes data från 
nationella register och insamlade journaluppgifter från 1,368 patienter med Barretts esofagus. 
 
10.2 METODER OCH RESULTAT 
Studie I utvärderade risken för matstrupscancer hos patienter med Barretts esofagus. 
Samtliga patienter med diagnosticerad Barretts esofagus i svenska patientregistret 
identifierades och följdes avseende på risk för matstrupscancer diagnosticerat i svenska 
cancerregistret. I de fall cancer inte diagnosticerats följdes patienterna till emigrations- eller 
dödsdatum, vilket identifierades via svenska befolkningsregistret, eller till studieperiodens 
slut. Totalt identifierades 7,932 patienter med Barretts esofagus, varav 89 patienter 
utvecklade matstrupscancer. De flesta tumörer diagnosticerades inom ett år efter diagnosen 
Barretts esofagus ställts och många av dessa förekom sannolikt redan vid den initiala 
diagnosen av Barretts esofagus. Efter det första året var risken för matstrupscancer mycket 
låg. Den årliga risken för cancer uppskattades till 0.15 %, vilket dock fortfarande var 9.4 
gånger högre än i den totala befolkningen i samma ålder, kön och kalenderår som de med 
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Barretts esofagus. Huvudbudskapet i denna studie var att patienter med Barretts esofagus har 
en lägre risk för matstrupscancer än man tidigare trott. 
Studie II utvärderade om patienter med Barretts esofagus kan klassas som hög- eller 
lågriskpatienter baserat på klinisk information såsom ålder, kön samt det endoskopiska 
utseendet av den förändrade slemhinnan. Patienter som utvecklat matstrupscancer eller dess 
förstadium (höggradig dysplasi) identifierades i patient- och cancerregistret och inkluderades 
som fall. Den kliniska informationen och endoskopibilden hos dessa patienter jämfördes med 
samma information hos kontrollpatienter med Barretts esofagus utan matstrupscancer eller 
höggradig dysplasi. Totalt identifierades 1,525 patienter vars journaluppgifter samlades in 
från sjukhus i hela Sverige. I slutändan inkluderades 1,368 patienter, varav 279 hade 
utvecklat matstrupscancer eller höggradig dysplasi. Efter genomgång av journaluppgifterna 
visade sig några variabler vara riskfaktorer för tumörutveckling: hög ålder, manligt kön och 
längre utbredning av Barretts esofagus. Andra misstänkta riskfaktorer, såsom inflammation i 
matstrupen och hiatusbråck, vilka båda är starkt kopplade till gastroesofageal refluxsjukdom, 
visade sig dock inte öka risken för matstrupscancer. En statistisk modell som byggde på de 
tre riskfaktorerna kunde förutsäga 71 % av matstrupscancrar, vilket kan anses vara acceptabel 
precision för att kunna bidra till en framtida mer skräddarsydd handläggning av patienter med 
Barretts esofagus. 
Studie III utvärderade om behandling av Barretts esofagus med tidiga (låggradiga) eller 
avancerade (höggradiga) cellförändringar (dysplasi) i Sverige följer de medicinska 
riktlinjerna. Riktlinjerna rekommenderar uppföljande gastroskopi eller gastroskopisk 
behandling för att upptäcka eller förhindra matstrupscancer hos dessa patienter. Patienterna 
identifierades från Studie II och följdes upp med patient-, cancer- och dödsorsaksregistret. 
Totalt inkluderades 211 patienter från 50 sjukhus som följdes under i median 3.9 år. Under 
denna period genomgick 84 % en uppföljande endoskopi, 17 % genomgick gastroskopisk 
behandling och 8 % genomgick kirurgisk behandling av matstrupen. Dock var hela 60 % av 
handläggandet inte i enlighet med medicinska riktlinjer, huvudsakligen på grund av 
underanvändning och tidsfördröjning av gastroskopi och behandling. Riskfaktorer för 
avvikande handläggning var låggradiga (jämfört med höggradiga) cellförändringar och längre 
utbredning av Barretts esofagus. Riktlinjer följdes mer strikt vid kirurgiska kliniker än vid 
medicinska kliniker. 
Studie IV utvärderade om användandet av magkikarundersökning (gastroskopi) för 
halsbränna minskar risken för död i matstrupscancer. Samtliga patienter i Sverige med 
matstrupscancer identifierades i cancerregistret och följdes med dödsorsakregistret till och 
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med död eller till slutet av studieperioden. Tidigare diagnos av gastroesofageal reflux eller 
gastroskopi identifierades från patientregistret under en tidsperiod före insjuknandet i cancer. 
Totalt identifierades 6,600 patienter med matstrupscancer varav hade 7 % en diagnos av 
gastroesofageal refluxsjukdom och 9 % genomgått en tidigare gastroskopi. Risken för död i 
matstrupscancer var oförändrad hos patienter som genomgått en eller två tidigare endoskopier 
(jämfört med de som inte hade genomgått någon endoskopi), medan patienter med 
gastroesofageal refluxsjukdom och tre eller fler endoskopier hade 45 % lägre risk att dö i 
matstrupscancer jämfört med de som inte hade genomgått någon tidigare endoskopi. 
 
10.3 DISKUSSION 
Risken för matstrupscancer hos patienter med Barretts esofagus är relativt hög första året 
efter diagnos, medan risken därefter är mycket låg. Vårdgivare bör därför vara särskilt 
uppmärksamma på tecken till tumörsjukdom omedelbart efter att Barretts esofagus 
diagnosticerats. Kunskapen om att risken är särskilt hög hos äldre män med längre utbredning 
av Barretts esofagus kan användas för en mer skräddarsydd uppföljning i framtiden, men 
forskning bör först förbättra möjligheterna att finna patienter med särskilt hög risk för 
matstrupscancer. Majoriteten av patienterna med Barretts esofagus handläggs inte enligt 
medicinska riktlinjer, vilka behöver implementeras i klinisk praxis. Effekten av gastroskopier 
för att förebygga död i matstrupscancer är begränsad, varför alternativa metoder bör 
eftersökas. 
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